|
Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
|
06 September 2023 |
|
Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
|
08 May 2023 |
|
Roche announces donation of essential medicines and diagnostic solutions to the people affected by the devastating earthquake in Türkiye and Syria
|
15 February 2023 |
|
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
|
20 January 2023 |
|
Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options
|
15 December 2022 |
|
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
|
12 August 2022 |
|
Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
|
04 August 2022 |
|
FDA grants Priority Review to Roche’s Lunsumio for people with relapsed or refractory follicular lymphoma
|
06 July 2022 |
|
FDA approves Roche’s Evrysdi for use in babies under two months with spinal muscular atrophy (SMA)
|
31 May 2022 |
|
Roche develops unique PCR tests to detect the monkeypox virus
|
27 May 2022 |
|
Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
|
17 May 2022 |
|
Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028
|
12 May 2022 |
|
U.S. FDA grants priority review to Roche's Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
|
04 April 2022 |
|
Roche donates additional medicines and diagnostics for Ukraine
|
30 March 2022 |
|
Roche announces donation of essential medicines to Ukraine
|
02 March 2022 |
|
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
|
14 February 2022 |
|
Roche completed the repurchase of Roche shares from Novartis
|
06 December 2021 |
|
CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease
|
11 November 2021 |
|
Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research
|
26 October 2021 |
|
Roche's anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer's disease
|
13 October 2021 |